Thyrocare Technologies Croissance future
Future contrôle des critères 5/6
Thyrocare Technologies devrait augmenter ses bénéfices et son chiffre d'affaires de 26.9% et de 16.3% par an respectivement. Le BPA devrait croître de de 27.2% par an. Le rendement des capitaux propres devrait être 25.3% dans 3 ans.
Informations clés
26.9%
Taux de croissance des bénéfices
27.2%
Taux de croissance du BPA
Healthcare croissance des bénéfices | 27.4% |
Taux de croissance des recettes | 16.3% |
Rendement futur des capitaux propres | 25.3% |
Couverture par les analystes | Low |
Dernière mise à jour | 24 Oct 2024 |
Mises à jour récentes de la croissance future
Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 26Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 04Recent updates
Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are
Oct 31Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump
Aug 01Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 26A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)
Jun 12Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult
Feb 29Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 04Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly
Dec 08Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 08Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively
Mar 23Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Mar 02Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First
Feb 01Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%
Jan 12The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares
Dec 24Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive
Dec 17Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 30Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher
Nov 02Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates
Nov 01Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
3/31/2027 | 9,319 | 1,647 | 2,087 | 2,074 | 2 |
3/31/2026 | 8,062 | 1,319 | 1,737 | 1,733 | 2 |
3/31/2025 | 6,828 | 998 | 1,595 | 1,559 | 2 |
9/30/2024 | 6,233 | 840 | 1,648 | 1,873 | N/A |
6/30/2024 | 5,939 | 776 | N/A | N/A | N/A |
3/31/2024 | 5,719 | 708 | 1,061 | 1,676 | N/A |
12/31/2023 | 5,535 | 655 | N/A | N/A | N/A |
9/30/2023 | 5,468 | 648 | 647 | 1,418 | N/A |
6/30/2023 | 5,338 | 599 | N/A | N/A | N/A |
3/31/2023 | 5,267 | 645 | 857 | 1,293 | N/A |
12/31/2022 | 5,214 | 731 | N/A | N/A | N/A |
9/30/2022 | 5,108 | 800 | 749 | 1,001 | N/A |
6/30/2022 | 5,520 | 1,423 | N/A | N/A | N/A |
3/31/2022 | 5,889 | 1,761 | 756 | 1,134 | N/A |
12/31/2021 | 6,051 | 1,924 | N/A | N/A | N/A |
9/30/2021 | 6,260 | 2,032 | 1,249 | 1,642 | N/A |
6/30/2021 | 6,030 | 1,685 | N/A | N/A | N/A |
3/31/2021 | 4,946 | 1,132 | 880 | 1,147 | N/A |
12/31/2020 | 4,503 | 741 | N/A | N/A | N/A |
9/30/2020 | 4,178 | 692 | 789 | 1,004 | N/A |
6/30/2020 | 3,797 | 612 | N/A | N/A | N/A |
3/31/2020 | 4,343 | 884 | 1,580 | 1,679 | N/A |
12/31/2019 | 4,384 | 1,063 | N/A | N/A | N/A |
9/30/2019 | 4,289 | 990 | 1,305 | 1,436 | N/A |
6/30/2019 | 4,165 | 892 | N/A | N/A | N/A |
3/31/2019 | 4,039 | 851 | 601 | 1,003 | N/A |
12/31/2018 | 3,946 | 939 | N/A | N/A | N/A |
9/30/2018 | 3,822 | 953 | N/A | N/A | N/A |
6/30/2018 | 3,663 | 947 | N/A | N/A | N/A |
3/31/2018 | 3,569 | 933 | N/A | 1,070 | N/A |
12/31/2017 | 3,493 | 1,117 | N/A | N/A | N/A |
9/30/2017 | 3,359 | 994 | N/A | N/A | N/A |
6/30/2017 | 3,258 | 759 | N/A | N/A | N/A |
3/31/2017 | 3,045 | 428 | N/A | 896 | N/A |
12/31/2016 | 2,843 | 659 | N/A | N/A | N/A |
9/30/2016 | 2,699 | 601 | N/A | N/A | N/A |
6/30/2016 | 2,535 | 564 | N/A | N/A | N/A |
3/31/2016 | 2,411 | 518 | N/A | 678 | N/A |
3/31/2015 | 1,835 | 452 | N/A | 345 | N/A |
3/31/2014 | 1,502 | 462 | N/A | 462 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de THYROCARE ( 26.9% par an) est supérieure au taux d'épargne ( 6.7% ).
Bénéfices vs marché: Les bénéfices de THYROCARE ( 26.9% par an) devraient croître plus rapidement que le marché Indian ( 18.1% par an).
Croissance élevée des bénéfices: Les bénéfices de THYROCARE devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de THYROCARE ( 16.3% par an) devrait croître plus rapidement que le marché Indian ( 10.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de THYROCARE ( 16.3% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de THYROCARE devrait être élevé dans 3 ans ( 25.3 %)